Participated · Series C · Aug 2026

Epicrispr Biotechnologies develops programmable epigenetic medicines designed to durably regulate gene expression without altering DNA sequence, leveraging its proprietary GEMS platform. Its lead program, EPI-321, is an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD) delivered in a single AAV vector intended to target muscle following intravenous administration. EPI-321 is in a Phase 1/2 trial with enrollment completed and interim results showing statistically significant increases in whole-body lean muscle volume, favorable biomarker changes consistent with DUX4 suppression, and a manageable safety profile. The company is advancing additional gene-modulating programs across multiple therapeutic areas and plans to expand its manufacturing capabilities. Epicrispr is based in San Francisco and is positioning to move EPI-321 into pivotal studies as it develops its next-generation programmable epigenetic medicines.

Participated · Series C · Jul 2026

Ratio Therapeutics is a clinical-stage pharmaceutical company that systematically engineers radiopharmaceuticals using its Trillium pharmacokinetic tuning technology and Macropa chelator platform. Its lead program, [Ac-225]RTX-2358, is in the ATLAS Phase 1/2 trial, and the broader pipeline includes a next-generation GRPR program, additional mono- and bispecific radioligand therapies, and imaging assets. The company has demonstrated external validation through partnered programs, including a collaboration with Novartis on an SSTR2 radioligand therapy. Ratio operates a hybrid manufacturing model with a vertically integrated manufacturing site in Utah, external partners, and diversified isotope supply. Financially, the company recently closed a $70 million Series C that brings total capital raised to over $240 million. Planned near-term activities include advancing the ATLAS trial, filing its fifth IND, moving the next-generation RLT into the clinic, expanding target indications, and scaling manufacturing to support future commercial demand.

Participated · Series D · Jan 2026

Cellares builds and operates fully automated platforms for cell therapy manufacturing, including the Cell Shuttle for end-to-end manufacturing and Cell Q for automated in-process and release quality control. The company says its automation delivers industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount. The Cell Shuttle has received the FDA's Advanced Manufacturing Technology (AMT) designation and the company reports a 100% automation success rate across more than a dozen automated processes. Cellares has achieved clinical validation milestones such as a successful IND amendment enabling active clinical manufacturing on the Cell Shuttle and the dosing of first patients in a partner clinical trial across multiple therapeutic areas and modalities. Headquartered in South San Francisco, Cellares operates a commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, and has additional facilities under construction in Europe and Japan. The company is positioning its network of IDMO Smart Factories to support both clinical and commercial programs and to expand access to cell therapies worldwide.

Participated · Series B · Dec 2025

Curative is reinventing employer-sponsored health insurance with a $0-out-of-pocket plan that waives co-pays, deductibles, and coinsurance when members complete an annual Baseline Visit. The plan uses AI-driven technology, real human guidance, and a Curative Cash Card that pays providers instantly to create a friction-free experience. Curative reports a 20% lift in primary-care engagement, a 30% reduction in hospitalizations, and up to 40% lower drug costs for groups in their first year. Launched less than three years ago, the company now serves more than 1,200 employer clients and over 165,000 members and is already profitable. Curative holds an A- AM Best rating, underscoring its financial strength. The firm plans to expand beyond its current Texas, Florida, and Georgia footprint into Mid-Atlantic states while deepening AI-enhanced operations and member engagement. Longer-term, Curative aims to replace legacy BUCA carriers by scaling its zero-cost, value-based model nationwide. The company’s current valuation, following its Series B, is $1.275 billion, giving it unicorn status.

Participated · Series C · Dec 2024

Precision Neuroscience is a New York City–based brain–computer interface (BCI) company led by CEO Michael Mager. The firm is developing what it describes as the only BCI that is minimally invasive, safely removable, and able to process large volumes of neural data. Its technology is aimed at delivering breakthrough treatments for millions of patients suffering from neurological illnesses by seamlessly interfacing with the brain. The design prioritizes patient safety and high-bandwidth data capture, distinguishing it from other implantable neurotech solutions. Newly secured funding will be used to expand operations and accelerate research and development efforts. The article did not disclose any revenue, user figures, or other operating metrics.